Study Summary
This trial is testing a new drug, HCW9218, to see if it is effective in treating advanced/metastatic solid tumor cancer. The drug is administered by injection and is a fusion protein complex that activates IL-15R signaling on effector immune cells.
- Solid Tumors
Treatment Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 12 months after 1st dose
Trial Safety
Awards & Highlights
Trial Design
1 Treatment Group
Administer HCW9218
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: HCW9218 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has HCW9218 received clearance from the Food and Drug Administration?
"HCW9218 is classified as a Phase 1 trial, so our team at Power assigned it a score of 1 due to the sparse clinical data supporting safety and efficacy." - Anonymous Online Contributor
Are there any remaining slots available in this medical experiment?
"According to the details available on clinicaltrials.gov, this trial has been actively recruiting participants since it was posted on April 1st 2022 and last updated a little over two weeks later." - Anonymous Online Contributor
What is the aggregate figure of participants taking part in this experiment?
"Absolutely. Evident on clinicaltrials.gov, the medical trial was first announced on April 1st 2022 and was revised most recently in mid-April; The research team is currently recruiting 24 people from a single clinic for participation." - Anonymous Online Contributor